July 11, 2022
The Effect of Ivermectin on the Viral Load and Culture Viability in Early Treatment of Non-Hospitalized Patients With Mild COVID-19
“Ivermectin, an anti-parasitic agent, also has anti-viral properties.
Our aim was to assess whether ivermectin has anti-SARS-CoV-2 activity.
The double-blinded trial compared patients receiving ivermectin for three days vs. placebo in non-hospitalized adult COVID-19 patients. RT-PCR from a nasopharyngeal-swab was obtained at recruitment and then every two days for at least 6 days.
Primary endpoint was reduction of viral-load on the sixth-day…
Out of 867 patients screened, ultimately 89 were per-protocol evaluable (47 ivermectin and 42 placebo). On day 6, OR was 2.62 (95% CI: 1.09-6.31) in ivermectin arm reaching the endpoint…
There were lower viral-loads and less viable-cultures in the ivermectin group, which shows its anti-SARS-CoV-2 activity.
It could lead to reduce transmission in these patients and encourage further studies with this drug.”
© CopyRights RawNews1st
